Non-Steroidal Anti-inflammatory Drugs Global Market Report 2025

Description

Non-steroidal anti-inflammatory drugs (NSAIDs) represent a class of medications designed to alleviate inflammation and reduce fever. They serve as remedies for various ailments including headaches, sprains, painful periods, common colds, flu, arthritis, and other chronic pain conditions. The primary function of NSAIDs is to mitigate inflammation, alleviate pain, and lower elevated body temperatures.

Administration of these drugs primarily occurs through oral ingestion, topical application, and other alternative methods. Topical application is particularly effective in alleviating muscle pains, sprains, and strains, offering relief for painful arthritic conditions. NSAIDs cater to a spectrum of disease indications encompassing arthritis, migraines, ophthalmic disorders, and other related ailments, being accessible through hospital pharmacies, retail outlets, and online pharmacy platforms.

The non-steroidal anti-inflammatory drugs market research report is one of a series of new reports from The Business Research Company that provides non-steroidal anti-inflammatory drugs market statistics, including non-steroidal anti-inflammatory drugs industry global market size, regional shares, competitors with a non-steroidal anti-inflammatory drugs market share, detailed non-steroidal anti-inflammatory drugs market segments, market trends and opportunities, and any further data you may need to thrive in the non-steroidal anti-inflammatory drugs industry. The non-steroidal anti-inflammatory drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-steroidal anti-inflammatory drugs market size has grown strongly in recent years. It will grow from $20.68 billion in 2024 to $22.1 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to chronic inflammatory diseases, postoperative pain management, sports injuries, over-the-counter availability, aging population, consumer awareness.

The non-steroidal anti-inflammatory drugs market size is expected to see strong growth in the next few years. It will grow to $28.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to emerging pain management therapies, regulatory changes, telehealth utilization, global wellness trends, biosimilar competition, patient preferences, precision medicine approaches. Major trends in the forecast period include over-the-counter (OTC) market dominance, rising preference for cox-2 inhibitors, generics and market competition, integration of digital health technologies, integration of digital health technologies.

The increasing prevalence of chronic pain is projected to drive the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market. Chronic pain is defined as discomfort that lasts for more than six months, and NSAIDs are commonly used to treat injuries and manage chronic pain. For example, a survey published in July 2022 by the U.S. Pain Foundation, a nonprofit organization based in the U.S., found that 96% of the 2,378 participants reported experiencing increased chronic pain, defined as pain persisting for three months or longer. This included 3% of caregivers and 1% of healthcare professionals surveyed from March to April 2022. Thus, the rising incidence of chronic pain is a key factor driving the growth of the NSAIDs market.

Increasing prevalence of musculoskeletal disorders (MSDs) is set to fuel the growth of the NSAIDs market. MSDs encompass a range of conditions impacting the musculoskeletal system and often requiring pain and inflammation management, for which NSAIDs serve as key therapeutic agents. Factors like an aging demographic, enhanced disease awareness, and greater orthopedic interventions contribute to this surge. A profile by GOV.UK in December 2022 highlighted the upsurge in the prevalence of MSDs among UK individuals aged 16 and above, pointing to a rise from 2021. This escalation underscores the market's trajectory, propelled by the increasing burden of musculoskeletal conditions and the role of NSAIDs in their management.

Product innovation is a significant trend in the non-steroidal anti-inflammatory drugs (NSAIDs) market. Leading companies in this sector are focusing on developing new technological solutions. For example, in February 2024, Hyloris Pharmaceuticals, a Belgium-based firm that specializes in reformulating existing drugs to meet unmet medical needs, launched Maxigesic IV. This intravenous formulation combines paracetamol (acetaminophen) and ibuprofen for the effective management of moderate to severe pain, particularly in postoperative settings. This combination offers enhanced analgesic effects compared to using either drug alone, resulting in more effective pain relief. The intravenous delivery of Maxigesic IV facilitates a rapid onset of action, making it well-suited for acute pain management in clinical environments.

Industry leaders in the NSAIDs market are pursuing new combination therapies to gain competitive advantages. Combination therapies entail the simultaneous use of multiple therapeutic agents or treatments to amplify efficacy or address diverse facets of a condition. For instance, in August 2022, Haleon PLC, a UK-based consumer healthcare company, introduced Advil PLUS Acetaminophen in Canada. This tablet combines ibuprofen and acetaminophen, providing a dual mechanism for pain relief across various pain types. The fusion of these two agents in a single tablet offers an accessible, non-prescription option for pain management, ensuring prolonged relief for up to eight hours. Advil PLUS Acetaminophen stands as an over-the-counter solution available in multiple retail outlets in Canada, showcasing the market's emphasis on effective combination therapies.

In March 2022, Pfizer, a prominent U.S.-based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals for an undisclosed sum. This strategic move enables Pfizer to access Arena Pharmaceuticals' diverse pipeline of developmental-stage therapeutic candidates primarily focused on dermatology, gastroenterology, and cardiology. Notably, this includes etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently undergoing development for various immuno-inflammatory diseases like Crohn's disease, ulcerative colitis, atopic dermatitis, eosinophilic esophagitis, and alopecia. Arena Pharmaceuticals, a U.S.-based company specializing in non-steroidal anti-inflammatory drugs, brings this portfolio of innovative treatments to Pfizer through this acquisition.

Major companies operating in the non-steroidal anti-inflammatory drugs market are Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc., Iroko Pharmaceuticals Inc., Reckitt Benckiser Group PLC, Perrigo Company PLC, Hikma Pharmaceuticals Public Limited Company, Glenmark Pharmaceuticals Limited, Septodont, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals Inc., Advanced Pharma Inc., Akorn Operating Company LLC, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Zydus Cadila Healthcare Limited, Aurobindo Pharma Limited, Sanofi S.A., GlaxoSmithKline PLC, Horizon Therapeutics PLC, Zyla Life sciences, Novartis AG, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company

North America was the largest region in the non-steroidal anti-inflammatory drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-steroidal anti-inflammatory drugs market during the forecast period. The regions covered in the non-steroidal anti-inflammatory drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-steroidal anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-steroidal anti-inflammatory drugs market consists of sales of high-dose aspirin, indomethacin, mefenamic acid, celecoxib, and other types. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Steroidal Anti-inflammatory Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-steroidal anti-inflammatory drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-steroidal anti-inflammatory drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-steroidal anti-inflammatory drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Route Of Administration: Oral; Topical; Other Route Of Administration
2) By Disease Indication: Arthritis; Migraine; Ophthalmic Diseases; Other Disease Indications
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Oral: Tablets; Capsules; Liquids Or Solutions
2) By Topical: Gels; Creams; Patches
3) By Other Route Of Administration: Injectable (Intravenous And Intramuscular); Suppositories
Companies Mentioned: Pfizer Inc.; Bayer AG; Johnson & Johnson; Sun Pharmaceutical Industries Ltd.; Assertio Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r22811

1. Executive Summary

2. Non-Steroidal Anti-inflammatory Drugs Market Characteristics

3. Non-Steroidal Anti-inflammatory Drugs Market Trends And Strategies

4. Non-Steroidal Anti-inflammatory Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Steroidal Anti-inflammatory Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Non-Steroidal Anti-inflammatory Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non-Steroidal Anti-inflammatory Drugs Market Growth Rate Analysis
5.4. Global Non-Steroidal Anti-inflammatory Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non-Steroidal Anti-inflammatory Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non-Steroidal Anti-inflammatory Drugs Total Addressable Market (TAM)

6. Non-Steroidal Anti-inflammatory Drugs Market Segmentation

6.1. Global Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Topical
Other Route of Administration
6.2. Global Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Arthritis
Migraine
Ophthalmic Diseases
Other Disease Indications
6.3. Global Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global Non-Steroidal Anti-inflammatory Drugs Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Capsules
Liquids Or Solutions
6.5. Global Non-Steroidal Anti-inflammatory Drugs Market, Sub-Segmentation Of Topical, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gels
Creams
Patches
6.6. Global Non-Steroidal Anti-inflammatory Drugs Market, Sub-Segmentation Of Other Route Of Administration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable (Intravenous And Intramuscular)
Suppositories

7. Non-Steroidal Anti-inflammatory Drugs Market Regional And Country Analysis

7.1. Global Non-Steroidal Anti-inflammatory Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non-Steroidal Anti-inflammatory Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market

8.1. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Steroidal Anti-inflammatory Drugs Market

9.1. China Non-Steroidal Anti-inflammatory Drugs Market Overview
9.2. China Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Steroidal Anti-inflammatory Drugs Market

10.1. India Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Steroidal Anti-inflammatory Drugs Market

11.1. Japan Non-Steroidal Anti-inflammatory Drugs Market Overview
11.2. Japan Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Steroidal Anti-inflammatory Drugs Market

12.1. Australia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Steroidal Anti-inflammatory Drugs Market

13.1. Indonesia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Steroidal Anti-inflammatory Drugs Market

14.1. South Korea Non-Steroidal Anti-inflammatory Drugs Market Overview
14.2. South Korea Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Steroidal Anti-inflammatory Drugs Market

15.1. Western Europe Non-Steroidal Anti-inflammatory Drugs Market Overview
15.2. Western Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Steroidal Anti-inflammatory Drugs Market

16.1. UK Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Steroidal Anti-inflammatory Drugs Market

17.1. Germany Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Steroidal Anti-inflammatory Drugs Market

18.1. France Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Steroidal Anti-inflammatory Drugs Market

19.1. Italy Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Steroidal Anti-inflammatory Drugs Market

20.1. Spain Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market

21.1. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market Overview
21.2. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Steroidal Anti-inflammatory Drugs Market

22.1. Russia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Steroidal Anti-inflammatory Drugs Market

23.1. North America Non-Steroidal Anti-inflammatory Drugs Market Overview
23.2. North America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Steroidal Anti-inflammatory Drugs Market

24.1. USA Non-Steroidal Anti-inflammatory Drugs Market Overview
24.2. USA Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Steroidal Anti-inflammatory Drugs Market

25.1. Canada Non-Steroidal Anti-inflammatory Drugs Market Overview
25.2. Canada Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Steroidal Anti-inflammatory Drugs Market

26.1. South America Non-Steroidal Anti-inflammatory Drugs Market Overview
26.2. South America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Steroidal Anti-inflammatory Drugs Market

27.1. Brazil Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Steroidal Anti-inflammatory Drugs Market

28.1. Middle East Non-Steroidal Anti-inflammatory Drugs Market Overview
28.2. Middle East Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Steroidal Anti-inflammatory Drugs Market

29.1. Africa Non-Steroidal Anti-inflammatory Drugs Market Overview
29.2. Africa Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Steroidal Anti-inflammatory Drugs Market Competitive Landscape And Company Profiles

30.1. Non-Steroidal Anti-inflammatory Drugs Market Competitive Landscape
30.2. Non-Steroidal Anti-inflammatory Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Assertio Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Non-Steroidal Anti-inflammatory Drugs Market Other Major And Innovative Companies

31.1. Iroko Pharmaceuticals Inc.
31.2. Reckitt Benckiser Group PLC
31.3. Perrigo Company PLC
31.4. Hikma Pharmaceuticals Public Limited Company
31.5. Glenmark Pharmaceuticals Limited
31.6. Septodont
31.7. Aspen Pharmacare Holdings Limited
31.8. Sagent Pharmaceuticals Inc.
31.9. Advanced Pharma Inc.
31.10. Akorn Operating Company LLC
31.11. Alembic Pharmaceuticals Limited
31.12. Torrent Pharmaceuticals Limited
31.13. Lupin Limited
31.14. Cipla Limited
31.15. Zydus Cadila Healthcare Limited

32. Global Non-Steroidal Anti-inflammatory Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Steroidal Anti-inflammatory Drugs Market

34. Recent Developments In The Non-Steroidal Anti-inflammatory Drugs Market

35. Non-Steroidal Anti-inflammatory Drugs Market High Potential Countries, Segments and Strategies

35.1 Non-Steroidal Anti-inflammatory Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Non-Steroidal Anti-inflammatory Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Non-Steroidal Anti-inflammatory Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer